Proactive Investors - Run By Investors For Investors

Tissue Regenix boss to take leave of absence to undergo medical treatment

Steve Couldwell will step aside in January in order to undergo treatment for an unspecified medical condition, although he should be back by March
steve couldwell
Chairman John Samuel will take over the reins in Couldwell’s absence

Steve Couldwell, the chief executive of regenerative medicines specialist Tissue Regenix Group PLC (LON:TRX), is taking a temporary leave of absence early next year in order to undergo medical treatment.

Couldwell will temporarily step aside in January and is expected to be out of action until March.

READ: TRX's CellRight subsidiary inks European distribution deal

In his absence, chairman John Samuel will become executive chairman, while chief financial officer Gareth Jones will take on the role of chief operating officer.

Samuel and Jones will hold those positions on an interim basis.

“Steve has done an excellent job of establishing a sound business strategy and delivering positive sales momentum,” said chairman Samuel.

“We are confident we will continue to execute against this strategy and on behalf of the Board and everyone at Tissue Regenix, I wish Steve a full and speedy recovery.”

As for current trading, a brief line at the end of the stock exchange announcement confirmed that the company remains on track to meet full-year expectations.

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use